Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term extension study of pegcetacoplan for C3 glomerulopathy or immune complex-mediated membranoproliferative glomerulonephritis
MOH_2024-03-13_013311Phase 3Not yet recruiting
- Sponsor
- Apellis Pharmaceuticals
- Start
- Dec 2023
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of pegcetacoplan in Complement 3 glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) (3 arms), sponsored by Apellis Pharmaceuticals. Primary endpoints: Long-term safety of pegcetacoplan and Long-term efficacy of pegcetacoplan. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on MOH_2024-03-13_013311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-03-13_013311.